This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (83)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ana Sanguineti, MD; J. Kevin Carmichael, MD, MS; Kim Campbell, PharmD

Arch Intern Med. 1993;153(9):1122-1124.

Abstract
Candida albicans is generally considered to be susceptible, in vivo, to fluconazole. In the population infected with human immunodeficiency virus, recurrent bouts of oral and esophageal candidiasis have led to increasing use of fluconazole for long-term prophylaxis. With prolonged therapy, the issue of developing resistance emerges. We report a case of fluconazole-resistant C albicans esophagitis that developed after fluconazole was used for more than 600 days.

(Arch Intern Med. 1993;153:1122-1124)

Author Affiliations
From the Department of Internal Medicine, Tucson (Ariz) Hospital Medical Education Program (Dr Sanguineti); the Department of Internal Medicine, Section of Infectious Disease, Department of Family Medicine, University of Arizona College of Medicine (Dr Carmichael); and the College of Pharmacy, University of Arizona, Tucson (Dr Campbell).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial
Pagani et al.
J Antimicrob Chemother 2002;50:231-240.
ABSTRACT | FULL TEXT  

Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis
Martinez et al.
J Antimicrob Chemother 2002;49:515-524.
ABSTRACT | FULL TEXT  

Rapid Identification of Yeasts in Positive Blood Cultures by a Multiplex PCR Method
Chang et al.
J. Clin. Microbiol. 2001;39:3466-3471.
ABSTRACT | FULL TEXT  

Evaluation of Etest for Direct Antifungal Susceptibility Testing of Yeasts in Positive Blood Cultures
Chang et al.
J. Clin. Microbiol. 2001;39:1328-1333.
ABSTRACT | FULL TEXT  

Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis
Weig and Müller
Antimicrob. Agents Chemother. 2001;45:966-968.
ABSTRACT | FULL TEXT  

A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
Martin-Mazuelos et al.
J Antimicrob Chemother 1999;43:477-481.
ABSTRACT | FULL TEXT  

Thirteen-Year Evolution of Azole Resistance in Yeast Isolates and Prevalence of Resistant Strains Carried by Cancer Patients at a Large Medical Center
Boschman et al.
Antimicrob. Agents Chemother. 1998;42:734-738.
ABSTRACT | FULL TEXT  

Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans: Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor
Vora et al.
Antimicrob. Agents Chemother. 1998;42:907-910.
ABSTRACT | FULL TEXT  

Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White et al.
Clin. Microbiol. Rev. 1998;11:382-402.
ABSTRACT | FULL TEXT  

Fluconazole as Prophylaxis Against Fungal Infection in Patients With Advanced HIV Infection
Manfredi et al.
Arch Intern Med 1997;157:64-69.
ABSTRACT  

Case 3-1995- A 29-year-old man with AIDS and multiple splenic abscesses
Fishman and Mattia
NEJM 1995;332:249-257.
FULL TEXT